The present invention provides methods of treating prediabetes, hyperglycemia, type 2 diabetes, AMIS syndrome, and obesity in a subject by administering to the patient HISS. The present invention also provides methods of diagnosing AMIS syndrome in a patient. Additionally, the present invention provides a method of shifting nutrient storage in meat-producing livestock to muscle rather than fat.

The present invention relates to a method for assessing a status of a wound of a patient, comprising the steps of determining a concentration of one or more inflammatory markers selected from glucose and eotaxin-1 in a sample from the wound, wherein the sample comprises or consists of wound fluid and the one or more inflammatory markers may indicate an inflammation within the wound, ii. determining a concentration of one or more bacterial markers in the sample, wherein the one or more bacterial markers may indicate a colonization of the wound with metabolically active bacteria, iii. assessing the status of the wound based on the concentrations of the one or more inflammatory markers and the one or more bacterial markers, wherein the status of the wound is assessed as being inflamed or not inflamed and as being colonized with metabolically active bacteria or not colonized with metabolically active bacteria. This diagnostic method allows a reliable, specific and detailed assessment of the status of the wound.

The present invention provides a biosensor system that can prevent a measurement error caused by the temperature of the environment in use from occurring. A biosensor system 100 includes a measuring instrument 101 having an operation part 306, and a sensor chip 200 that is insertable into and removable from the measuring instrument 101 and into which a blood sample is introduced. The sensor chip 200 includes a measurement part 41 (a measurement part A) that acquires Data a related to the concentration of an analyte in a blood sample based on the amount of electric current that flows in the blood sample due to a reaction in which an oxidoreductase with the analyte used as a substrate is involved, and a measurement part 42 (a measurement part B) that acquires, from the blood sample, Data b for temperature correction of Data a. The operation part 306 has a function of determining the concentration of the analyte in the blood sample, with the concentration having been corrected according to the temperature of the blood sample based on Data a and Data b.

The present invention encompasses a glucose indicator protein, a biosensor comprising one or more glucose indicator proteins, and methods of use thereof.

The present invention encompasses a glucose indicator protein, a biosensor comprising one or more glucose indicator proteins, and methods of use thereof.

A method and an apparatus are described for the generation of microparticles containing an immobilized functional component, where the following measures are proposed: spraying a liquid (32) containing a soluble alginate and a functional component consisting of molecules or nanoparticles to generate a stream (60) of droplets, directing the stream (60) of droplets onto a precipitation bath (16) and capturing the droplets therein by application of high voltage (14), precipitating the droplets in the precipitation bath (16) via a precipitation liquid (18) containing an alginate complexing agent, such that the droplets are solidified to form microparticles (10) containing the functional component and extracting the microparticles (10) from the precipitation bath (16).

A method and an apparatus are described for the generation of microparticles containing an immobilized functional component, where the following measures are proposed: spraying a liquid (32) containing a soluble alginate and a functional component consisting of molecules or nanoparticles to generate a stream (60) of droplets, directing the stream (60) of droplets onto a precipitation bath (16) and capturing the droplets therein by application of high voltage (14), precipitating the droplets in the precipitation bath (16) via a precipitation liquid (18) containing an alginate complexing agent, such that the droplets are solidified to form microparticles (10) containing the functional component and extracting the microparticles (10) from the precipitation bath (16).

The claimed invention provides personalized glucose and insulin information to a user in need thereof. Non-invasive body fluid capture techniques utilize saliva to provide body levels of glucose and insulin as well as optional pharmaceutical ingestion coordinated over time. Saliva captured on cellulose strips are analyzed in real time using oxidation and aptamer conjugate hybridization together with traditional analytical chemistry techniques including liquid chromatography/mass spectrometry (LC/MS) and coordinated against time of pharmaceutical administration. By embracing the P4 (Participatory, Personalized, Predictive, and Preventive) health management method the patient can determine glucose and insulin related wellness levels and if a pharmaceutical is having the correct and desired effect for maximum therapeutic benefit.

The claimed invention provides personalized glucose and insulin information to a user in need thereof. Non-invasive body fluid capture techniques utilize saliva to provide body levels of glucose and insulin as well as optional pharmaceutical ingestion coordinated over time. Saliva captured on cellulose strips are analyzed in real time using oxidation and aptamer conjugate hybridization together with traditional analytical chemistry techniques including liquid chromatography/mass spectrometry (LC/MS) and coordinated against time of pharmaceutical administration. By embracing the P4 (Participatory, Personalized, Predictive, and Preventive) health management method the patient can determine glucose and insulin related wellness levels and if a pharmaceutical is having the correct and desired effect for maximum therapeutic benefit.

Disclosed are methods and kits for analyzing a sample comprising 1,5-anhydroglucitol and a possible first analyte via one or more chemiluminescent reactions. Certain embodiments include measuring a first light response resulting from a first chemiluminescent reaction and measuring a second light response resulting from a second chemiluminescent reaction. Certain embodiments also include comparing the first light response to the second light response to determine a ratio of 1,5-anhydroglucitol and the first analyte. Also provided are kits including reagents for practicing the claimed methods.